Introduction {#s1}
============

Internet-delivered cognitive behavior therapy (ICBT) has existed for more than 20 years ([@B1]), and treatment programs have been developed for a wide range of clinical and non-clinical conditions. Most forms of ICBT are administered in the form of guided self-help, with text and video presentations boosted by email support in a secure online platform resembling Internet banking ([@B2]). One way to describe ICBT is to pinpoint the similarities with online education, even if the treatment is largely based on self-help texts and cognitive behavioral therapy (CBT) manuals ([@B3]). Thus, ICBT programs tend to rely on psychoeducation and instructions for how to change thoughts, emotions, and behaviors in everyday life, and, like CBT, programs usually last 5 to 15 weeks with homework assignments and therapist feedback provided on a weekly basis ([@B3]).

Research suggests that therapist-supported ICBT---in contrast to unguided treatments ([@B4])---can be as effective as face-to-face cognitive behavior therapy ([@B5]), yield long-term results ([@B6]), and work under clinically representative conditions ([@B7]). ICBT has also been tested for different target groups---for example, young persons ([@B8]), adults ([@B9]), older persons ([@B10]), and immigrants ([@B11]). Treatment programs have focused on specific problems, such as procrastination ([@B12]); diagnoses like post-traumatic stress disorder (PTSD) ([@B13]); or tailored according to a client's specific problem profile ([@B14]). Another approach has been to deliver transdiagnostic treatments in which one treatment is used to target underlying common processes, such as avoidance ([@B15]). There are also studies on other psychotherapy forms, including psychodynamic psychotherapy (e.g., [@B16]), interpersonal psychotherapy ([@B17]), versions of CBT such as acceptance and commitment therapies ([@B18]), and attention training ([@B19]). Finally, there are also programs based on physical exercise ([@B20]), mindfulness ([@B21]), and relaxation ([@B22]), even if the latter two are often incorporated into ICBT protocols ([@B23]). In addition to the controlled trials, several studies exist on moderators and mediators of outcome (e.g., [@B24]), as well as some qualitative studies on the client's experience during ICBT ([@B25]).

While it is common to report effects in clinical trials, there are also studies and reviews reporting negative effects and non-response to ICBT. In two previous individual patient data meta-analyses (IPDMA), we studied these two outcomes ([@B26], [@B27]). With regards to negative effects in the form of deterioration, 5.8% of treated research participants showed such effects ([@B26]), and non-response was present among 26.8% of participants ([@B27]). When completing these two reviews based on our dataset of controlled trials, a question emerged regarding response rates in our ICBT studies as this was not reported in the previous ones given uncertainties regarding definitions and scope of the two previous reviews. In contrast to the standard of reporting mean standardized differences with metrics like Cohen's *d*, there is far less agreement on how to define response in psychological treatments studies in general, and specifically in CBT ([@B28]). Several questions emerge when defining what constitutes a "response" to treatment. In a review, [@B26], p. 73-74) mentioned several issues, such as (a) number of measures used to define response, (b) number of modalities (e.g., self-report *versus* observed behavior), (c) blinding of assessors, (d) degree of change from baseline, and (e) use of a clinical cut-off to determine if a client has reached a non-clinical state (sometimes referred to as high end-state or remission). In a seminal paper, Jacobson and Truax ([@B29]) outlined guidelines for defining change from baseline (reliable change index-RCI) and different ways to define what constitutes being within a non-clinical range or having reached high end-state function/remission. In the present review, we will use the term "remission" to refer to what can be counted as high end-state function, which allows us to be consistent with a previous IPDMA on depression by Karyotaki et al. ([@B30]).

In their IPDMA on guided ICBT for depression focusing on response and remission, Karyotaki et al. ([@B30]) included 24 RCTs (4,889 participants) and compared guided ICBT with a control group. The mean pooled response rate (based on RCI) at post-treatment was 56.19%, and the mean remission rate at post-treatment in the treatment groups (N = 26) was 38.51% based on the RCI criteria (1.96)---two standard deviations improvement from baseline for each measure. Given the dataset we coded based on our own trials, we decided to conduct a new IPDMA ([@B31]) knowing that we could use original data across studies to investigate reliable change and remission (high end-state function). As in our previous two IPDMAs ([@B26], [@B27]), we used data from 29 clinical trials. The final dataset with complete data consisted of 1,535 patients who had received ICBT, and trials were categorized into three groups: anxiety disorders, depression/mood disorders, and other conditions (i.e., erectile dysfunction, relationship problems, and gambling disorder). The aim of the current study was to determine the rates of treatment response and remission in clients who had received ICBT in clinical trials conducted by our group in Sweden. As a secondary exploratory aim, we examined potential predictors of response.

Materials And Methods {#s2}
=====================

Individual Patient Data Meta-Analysis {#s2_1}
-------------------------------------

As described in our two previous IPDMAs ([@B26], [@B27]), we used the scores for individual client and outcome variable across studies ([@B32]). In IPDMAs, it is study factors that might be predictive of treatment outcome using the raw data instead of group means, as has been done in previous IPDMAs---for example, on low-intensity psychological treatments ([@B33]) and Internet interventions for problem drinking ([@B34]). As in the previous IPDMAs, we aggregated available data from clinical trials that we conducted. A complete description surrounding our data collection procedure is presented in Rozental et al. ([@B26]). An obvious limitation of using this method is that we cannot assess the risk of bias, which is a common practice in systematic reviews ([@B32]). However, by including trials from our own group, we were able to obtain an overall view of response and remission, which we assume could be representative, particularly for Swedish settings. For a complete description of the inclusion and exclusion criteria used, see [@B26], p.163).

The raw scores from each client in the included trials were entered into one data matrix, and codes for background variables were aligned. Given the complexity of modeling reasons for missing data in such a heterogeneous group of research participants and the fact that we were focused on binary outcomes in this review, we decided to use a complete case approach instead of multiple imputation, as we were convinced that data were not missing completely at random ([@B35]). Moreover, complete case analysis has been recommended as the first approach when conducting meta-analyses, even if this approach is followed by sensitivity analyses to detect possible bias in estimates ([@B36]).

Sociodemographic variables were occasionally collapsed to facilitate comparisons and to obtain consistency across trials (see [@B26], [@B27]). Trials were categorized into three categories: (1) anxiety disorders, (2) depression and mood disorders, and (3) other (i.e., erectile dysfunction, relationship problems, and gambling disorder). In [**Table 1**](#T1){ref-type="table"}, we present an overview of the clients' sociodemographic variables in the trials included (the table overlaps with [**Table 3**](#T3){ref-type="table"} in [@B26], p. 169 but does not include the control groups). We present data from baseline in the trials and also the amount of missing data for the full sample.

###### 

Sociodemographic characteristics of the participants included in the analysis (based on [Table 3](#T3){ref-type="table"} in [@B26]).

  Baseline characteristic                                                     ICBT (*n* = 1,864)   Full sample (*n* = 2,866)                          Missing data for the full sample
  --------------------------------------------------------------------------- -------------------- -------------------------------------------------- --------------------------------------------------
  Gender: *n* (% female)                                                      1,120 (61.0)         1,800 (63.4) [^a^](#fnT1_1){ref-type="table-fn"}   27 (0.9) [^b^](#fnT1_2){ref-type="table-fn"}
  Age (years): *M* (*SD*)                                                     40.4 (16.0)          38.7 (12.8)                                        29 (1)
  Civil status: *n* (%)                                                                                                                               744 (27)
  Single                                                                      419 (32.7)           668 (31.9)                                         
  Relationship                                                                861 (67.3)           1,424 (68.1)                                       
  Children: *n* (% yes)                                                       506 (54.4)           780 (55)                                           1,446 (50.5)
  Cohabitant: *n* (% yes)                                                     256 (65.6)           354 (12.4)                                         2,337 (81.5)
  Highest educational level: *n* (%)                                                                                                                  1,099 (38.3)
  Elementary school                                                           46 (4.1)             86 (4.9)                                           
  High school/college                                                         335 (30.1)           530 (30)                                           
  University                                                                  720 (64.7)           1,137 (64.3)                                       
  Postgraduate                                                                12 (1.1)             14 (0.8)                                           
  Employment: *n* (%)                                                                                                                                 1,968 (68.7)
  Unemployed                                                                  65 (11.2)            93 (10.4)                                          
  Student                                                                     78 (13.4)            138 (15.4)                                         
  Employed                                                                    402 (69.1)           607 (67.6)                                         
  Other                                                                       12 (2.1)             24 (2.7)                                           
  Retired                                                                     25 (4.3)             36 (4)                                             
  Primary diagnosis: *n* (%)                                                                                                                          88 (3.1)
  Anxiety disorders                                                           930 (51.5)           1,681 (60.5)                                       
  Generalized anxiety disorder                                                141 (7.8)            279 (10)                                           
  Social anxiety disorder                                                     541 (30.0)           965 (34.7)                                         
  Anxiety disorder NOS                                                        11 (0.6)             31 (1.1)                                           
  Panic disorder (with/without agoraphobia)                                   61 (3.4)             116 (4.2)                                          
  Posttraumatic stress disorder                                               32 (1.8)             64 (2.3)                                           
  Anxiety disorder (with/without depression)                                  117 (6.5)            173 (6.2)                                          
  Specific phobia                                                             26 (1.4)             53 (1.9)                                           
  Depression (with/without dysthymia)                                         439 (24.3)           544 (19.6)                                         
  Other                                                                       436 (24.2)           553 (19.9)                                         
  Erectile dysfunction                                                        39 (2.2)             78 (2.8)                                           
  Relationship problems                                                       80 (4.4)             158 (5.7)                                          
  Gambling disorder                                                           317 (17.6)           317 (11.4)                                         
  Sick leave: *n* (% yes)                                                     41 (5.9)             67 (6.1)                                           1,768 (61.7)
  Previous psychological treatment: *n* (% yes)                               534 (55.8)           789 (54.7)                                         1,424 (49.7)
  Previous or ongoing psychotropic medication: *n* (% yes)                    336 (32.0)           522 (32.1)                                         1,239 (43.2)
  Satisfaction with treatment: *M (SD)* [^c^](#fnT1_3){ref-type="table-fn"}   2.9 (1)              2.9 (1)                                            1,867 (88.2)[^e^](#fnT1_5){ref-type="table-fn"}
  Treatment credibility: *M (SD)* [^d^](#fnT1_4){ref-type="table-fn"}         7.2 (2.5)            7 (2.4)                                            1,535 (72.5) [^e^](#fnT1_5){ref-type="table-fn"}
  Modules completed: *M (SD)* [^f^](#fnT1_6){ref-type="table-fn"}             6.6 (2.5)            6.5 (1.3)                                          1,194 (56.4) [^e^](#fnT1_5){ref-type="table-fn"}
  Time per week: *M (SD)* [^g^](#fnT1_7){ref-type="table-fn"}                 3.7 (3.0)            3.6 (3.1)                                          1,722 (81.3) [^e^](#fnT1_5){ref-type="table-fn"}

n.a., not applicable; NOS, not otherwise specified.

Valid percent, i.e., percent of available data, excluding missing data.

Percent, i.e., percent of complete dataset, including missing data.

Self-rated 0--5.

Self-rated 0--10.

Based on patients receiving treatment.

Weighted mean and standard deviation.

Number of hours per week.

Statistical Analysis {#s2_2}
--------------------

The RCI was chosen based on its widespread use for assessing reliable change ([@B29], [@B37]). As is common practice, the RCI was calculated by taking each individual change score and then dividing this score by the standard error of the difference, i.e., *SE* ~diff~ = *SD* ~1~√2√1-*r*. In the formula, *SD* ~1~ corresponds to the standard deviation of a condition at pre-treatment, and *r* is the reliability estimate ([@B38]). We calculated RCIs for the primary outcome measure of each included trial and used the test--retest reliability for that specific trial measure (see [**Table 2**](#T2){ref-type="table"}; also reported in [@B27]). Basically, the RCI sets the limit for when a change score is unlikely to be real (*p* = .05). Following the usual standards, we calculated RCIs for which a change equal to *z* = 1.96 on the basis of a standard deviation unit was used. Following this, each participant in the trials could be classified as either a responder or a non-responder to treatment, with the definition of response being specific to each study and measure used, a similar method to that used by Karyotaki et al. ([@B30]). Heterogeneity was tested by entering response rates into the program comprehensive meta-analysis (version 2.2.021; CMA).

###### 

Test-retest reliabilities used for calculating improvement rates based on the reliable change index (same Table as in [@B27], p. 6).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Primary outcome                                                                                Test--retest reliability                                Time period                           Population   Reference
  ---------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------- ------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Beck Anxiety Inventory                                                                         *r* = 0.81                                              2 weeks                               Normal       Saemundsson et al. ([@B39])

  Liebowitz Social Anxiety Scale---self-report                                                   *r* = 0.93                                              8 weeks                               Normal       Heeren et al. ([@B40])

  Panic Disorder Severity Scale---self-report                                                    *ρ* = 0.94                                              2 days                                Patient      Lee et al. ([@B41]). Reliability and validity of the self-report version of the Panic Disorder Severity Scale in Korea. *Depression and anxiety, 26(8)*, E120-E123.

  Patient Health Questionnaire---nine items                                                      *r* = 0.94                                              2 weeks                               Patient      Zuithoff et al. ([@B42])

  International index of erectile functioning---five items [^a^](#fnT2_1){ref-type="table-fn"}   *r*= 0.84                                               4 weeks                               Patient      Rosen et al. ([@B43])

  Beck Depression Inventory                                                                      *r* = 0.77                                              [^b^](#fnT2_2){ref-type="table-fn"}   Normal       Beck and Steer ([@B44])

  Impact of Event Scale---revised                                                                *r* = 0.89--0.94 [^c^](#fnT2_3){ref-type="table-fn"}\   6 months                              Patient      Sundin and Horowitz, ([@B45])
                                                                                                 *M* = 0.92                                                                                                 

  Generalized Anxiety Disorder---seven items                                                     ICC = 0.83                                              1 week                                Patient      Spitzer et al. ([@B46])

  Penn State Worry Questionnaire                                                                 *r* = 0.84                                              3 weeks                               Normal       Pallesen et al. ([@B47])

  Body Sensations Questionnaire                                                                  *r* = 0.89                                              3 months                              Patient      Arrindell ([@B48])

  Dyadic Adjustment Scale [^a^](#fnT2_1){ref-type="table-fn"}                                    *r* = 0.87                                              2 weeks                               Patient      Carey et al. ([@B49])

  Snake Anxiety Questionnaire                                                                    *r* = 0.78                                              1 month                               Normal       Klorman et al. ([@B50])

  Montgomery--Åsberg Depression Rating Scale---self-report                                       ICC = 0.78                                              1 week                                Patient      Fantino and Moore, ([@B51])

  Spider Phobia Questionnaire                                                                    *r* = 0.94                                              3 weeks                               Normal       Muris and Merckelbach, ([@B52])

  The NORC Diagnostic Screen for Gambling Problems                                               *r* = 0.98--0.99 [^d^](#fnT2_4){ref-type="table-fn"}\   1 week                                Patient      Gerstein et al. ([@B53])
                                                                                                 *M* = 0.98                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NORC, a National Organization for Research at the University of Chicago.

Reversed scales, higher scores indicate less problems.

Information regarding the time period was unavailable.

Separate estimates for the two subscales.

Lifetime test statistic and past year test statistic.

We also followed the methods of Karyotaki et al. ([@B30]) when calculating remission, again using criteria set by Jacobson and Truax ([@B29]). Participants were classified as remitters if they moved two standard deviations below the mean of the clinical group to which they belonged in each study. The resulting cut-off scores indicates remission, which is a hard criterion of remission, often being equivalent to a symptom-free state. For six of the studies, it was not possible to use the two standard deviation criteria due to floor effects, so instead, we used one standard deviation as the criterion in these cases.

In order to investigate possible predictors, we applied binomial logistic regression and used either response or recovery rates as dependent variables. All variables were entered into the model simultaneously. In terms of the variables used, we selected a few clinically relevant demographic and clinical predictors ([@B54]) ([@B31]). We selected the same variables as in our previous IPDMAs on deterioration ([@B26]) and non-response ([@B27]). The predictors were (a) symptom severity at baseline, (b) civil status, (c) age, (d) sick leave, (e) previous psychological treatment, (f) previous or ongoing psychotropic medication, (g) educational level, (h) diagnosis, and (i) gender. We also added a separate analysis of the association between publication year and the two outcomes response and recovery.

We present odds ratios (OR) with 95% confidence intervals (CI) in order to reflect an increase or decrease in odds of response and remission in relation to a reference category. In the case of dichotomous predictors (such as gender), the OR reflects the odds of response or remission when a client is female *versus* male (reference). A positive OR thus means better response in women. For continuous predictors (symptom severity at baseline and age), the OR instead represents an increase of one standard deviation above their respective mean. The statistical analyses on predictors were performed using jamovi version 0.9.2.9 ([@B55]), with the proportions of response and remission performed on a complete case basis (see online [**Supplementary Material**](#SM1){ref-type="supplementary-material"}).

Ethics {#s2_3}
------

The data in the current IPMA were derived from several clinical trials, all of which had received ethical approval from the respective regional ethical review boards at each study location.

Results {#s3}
=======

Study Characteristics {#s3_1}
---------------------

The 29 clinical trials were coded according to the previously predefined inclusion and exclusion criteria and deemed eligible for the current IPDMA (see [@B26], [@B27] for further details). Raw scores from all clients were entered into one spread sheet. The exception was 46 clients who had received either psychodynamic psychotherapy or interpersonal psychotherapy *via* the Internet as a control condition. In total, 1,535 clients were included in this IPDMA. The following diagnoses were included (clinical trials, *k*): social anxiety disorder ([@B9]), depression (with/without dysthymia) (5), generalized anxiety disorder (3), anxiety disorder (with/without depression) (3), mixed anxiety disorders (e.g., panic disorder as well as social anxiety disorder) (2), specific phobia (2), posttraumatic stress disorder (1), panic disorder (with/without agoraphobia) (1), gambling disorder (1), erectile dysfunction (1), and relationship problems (1) (see [@B26], p.6). Briefly, most participants in the trials had been recruited from the general population based on self-referral (n = 27). A common practice in the trials was to use structured telephone interviews such as the Structured Clinical Interview for DSM-IV-Axis I Disorders ([@B56]) or the MINI-International Neuropsychiatric Interview ([@B57]). Some studies had used diagnosis-specific instruments such as the Clinician-Administered PTSD Scale ([@B58]). For a description of treatment content original studies, (see [@B26], [@B27]). The amount of missing data for the primary outcome measures at post-treatment was 12.9%. A complete overview of the clinical trials is presented in [**Table 3**](#T3){ref-type="table"} (which to some extent overlaps with [**Table 3**](#T3){ref-type="table"} in [@B27] but with different results presented).

###### 

Characteristics and rates of improvement and recovery for the clinical trials included in the individual patient data meta-analysis.

  Study                         Recruitment          Screening interview                 Primary diagnosis                                                                             Treatment (*n*)                                                                                                                         Control (*n*)                                                     Modules/weeks or sessions                                           Primary outcome                                        Additional outcomes                                  Improvement *n* (%)\*   Recovery *n* (%)\*
  ----------------------------- -------------------- ----------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------- ----------------------- --------------------
  IMÅ ([@B21])                  General population   SCID-I                              Panic disorder, social anxiety disorder, generalized anxiety disorder, anxiety disorder NOS   Unguided mindfulness with FAQ (42)                                                                                                      Wait-list with discussion forum (46)                              8 modules/8 weeks                                                   BAI                                                    BDI, QOLI, ISI                                       26 (66.7%)              23 (59.0%)
  ACT Smart ([@B59])            General population   SCID-I                              Panic disorder, social anxiety disorder                                                       Unguided ACT (48), guided ACT (48)                                                                                                      Wait-list (47)                                                    8 modules/10 weeks                                                  LSAS-SR, PDSS-SR [^a^](#fnT3_1){ref-type="table-fn"}   PHQ-9, GAD-7, QOLI                                   38 (49.4%)              8 (10.4%)
  ACTUA ([@B60])                General population   SCID-I                              Depression                                                                                    Guided physical activity (164), guided behavioral activation (158) [^b^](#fnT3_2){ref-type="table-fn"}                                  n.a.                                                              8 modules/12 weeks                                                  PHQ-9                                                  GAD-7, QOLI [^c^](#fnT3_3){ref-type="table-fn"}      146 (75.3%)             84 (43.3%)
  ADAM ([@B61])                 General population   Semi-structured interview, IIEF-5   Erectile dysfunction                                                                          Guided CBT (39)                                                                                                                         Wait-list with discussion forum (39)                              7 modules/7 weeks                                                   IIEF-5                                                 IIEF, RAS, BDI, BAI                                  4 (12.1%)               0 (0.0%)
  Challenger ([@B62])           General population   MINI                                Social anxiety disorder                                                                       Unguided CBT with smartphone application (68), unguided bibliotherapy (70)                                                              Wait-list (69)                                                    9 modules/6 weeks                                                   LSAS-SR                                                GAD-7, PHQ-9, QOLI, BBQ, Mini-SPIN                   40 (62.5%)              18 (28.1%)
  Stella ([@B63])               General population   SCID-I and II                       Depression                                                                                    Guided CBT (33), group therapy (36), guided CBT as preferred choice (16)                                                                n.a.                                                              8 modules/8 weeks, 8 sessions                                       BDI                                                    MADRS-S, BAI, HAM-D, QOLI,                           27 (57.5%)              0 (0.0%)
  Depressionshjälpen ([@B64])   General population   SCID-I                              Depression                                                                                    Guided CBT (40)                                                                                                                         Wait-list (40)                                                    7 modules/8 weeks                                                   BDI                                                    MADRS-S, BAI, QOLI, WAI                              26 (66.7%)              2 (5.1%)
  Tellus ([@B65])               General population   CAPS                                Posttraumatic stress disorder                                                                 Guided CBT (31)                                                                                                                         Wait-list with support (31) [^d^](#fnT3_4){ref-type="table-fn"}   8 modules/8 weeks                                                   IES-R                                                  PDS, BDI, BAI, QOLI                                  21 (75%)                11 (39.3%)
  Klara ([@B66])                General population   SCID-I                              Depression                                                                                    Guided CBT (29), guided CBT*via*email (30)                                                                                              Wait-list (29)                                                    7 modules/8 weeks                                                   BDI                                                    MADRS-S, BAI, QOLI                                   47 (83.9%)              4 (7.1%)
  Oroshjälpen ([@B18])          General population   SCID-I                              Generalized anxiety disorder                                                                  Guided ACT (52)                                                                                                                         Wait-list (51)                                                    7 modules/9 weeks                                                   GAD-7                                                  PSWQ, GAD-Q-IV, BAI, MADRS-S, PHQ-9, QOLI            27 (64.3%)              15 (35.7%)
  Nova 1 ([@B67])               General population   SCID-I                              Anxiety disorder with/without comorbid depression                                             Guided CBT (53)                                                                                                                         n.a.                                                              10 modules/10 weeks [^e^](#fnT3_5){ref-type="table-fn"}             BAI                                                    MADRS-S, CORE-OM, QOLI                               21 (42.0%)              14 (28.0%)
  Nova 2 ([@B68])               Primary care         SCID-I                              Anxiety disorder with/without comorbid depression                                             Guided CBT (51)                                                                                                                         Wait-list (50)                                                    10 modules/10 weeks [^f^](#fnT3_6){ref-type="table-fn"}             BAI                                                    MADRS-S, CORE-OM, QOLI                               15 (39.5%)              1 (2.6%)
  Origo 1 ([@B23])              General population   SCID-I                              Generalized anxiety disorder                                                                  Guided CBT (44)                                                                                                                         Wait-list (45)                                                    8 modules/8 weeks                                                   PSWQ                                                   GAD-Q-IV, STAI, BAI, BDI, MADRS-S, QOLI              23 (62.2%)              14 (37.8%)
  Origo 2 ([@B69])              General population   SCID-I                              Generalized anxiety disorder                                                                  Guided CBT (27) [^g^](#fnT3_7){ref-type="table-fn"}                                                                                     Wait-list (27)                                                    8 modules/8 weeks                                                   PSWQ                                                   GADQ-IV, MADRS-S, BDI, BAI, STAI, QOLI               11 (47.8%)              4 (17.4%)
  Panik 2 ([@B70])              General population   SCID-I, CIDI                        Panic disorder                                                                                Guided CBT (25), face-to-face CBT (24)                                                                                                  n.a.                                                              10 modules/10 weeks, 10 sessions                                    BSQ                                                    ACQ, MI, BAI, BDI, QOLI                              17 (68.0%)              10 (40.0%)
  Pia^1^                        General population   SCID-I                              Relationship problems                                                                         Guided CBT (80)                                                                                                                         Wait-list with discussion forum (78)                              10 modules/10 weeks                                                 DAS                                                    MSI, BDI, BAI, QOLI                                  21 (31.3%)              7 (10.5%)
  Progredi ([@B20])             General population   SCID-I                              Depression                                                                                    Guided CBT with physical activity (24)                                                                                                  Wait-list (24)                                                    9 modules/9 weeks                                                   MADRS-S                                                BDI, BAI, QOLI [^c^](#fnT3_3){ref-type="table-fn"}   15 (62.5%)              10 (41.7%)
  Fobal snake ([@B71])          General population   SCID-I                              Specific phobia                                                                               Guided CBT (13), face-to-face CBT (13)                                                                                                  n.a.                                                              4 modules/4 weeks, 2 sessions [^h^](#fnT3_8){ref-type="table-fn"}   SNAQ                                                   ADIS, FSS, BAI, BDI                                  10 (83.3%)              7 (58.3%)
  Sofie 13 ([@B72])             General population   SCID-I                              Social anxiety disorder                                                                       Guided CBT with CBM (61), Guided CBT without CBM (65),                                                                                  n.a.                                                              9 modules/9 weeks [^i^](#fnT3_9){ref-type="table-fn"}               LSAS-SR                                                SIAS, SPS, MADRS-S, QOLI                             88 (73.5%)              41 (34.5%)
  Sofie 9 ([@B73])              General population   SCID-I and II                       Social anxiety disorder                                                                       Guided CBT (40)                                                                                                                         Attention bias modification (39)                                  9 modules/9 weeks                                                   LSAS-SR                                                SIAS, SPS, SPSQ, BAI, MADRS-S, QOLI                  27 (73.0%)              0 (0.0%)
  Sofie 12 ([@B74])             General population   SCID-I, MINI                        Social anxiety disorder                                                                       Guided CBT with smartphone application (24) [^j^](#fnT3_10){ref-type="table-fn"}                                                        n.a.                                                              9 modules/9 weeks                                                   LSAS-SR                                                k                                                    19 (79.2%)              7 (29.2%)
  Sofie 1 ([@B75])              General population   SCID-I                              Social anxiety disorder                                                                       Guided CBT (32)                                                                                                                         Wait-list (32)                                                    9 modules/9 weeks                                                   LSAS-SR                                                SIAS, SPS, SPSQ, BAI, MADRS-S, QOLI                  22 (75.9%)              7 (24.1%)
  Sofie 2 ([@B76])              General population   SCID-I                              Social anxiety disorder                                                                       Guided CBT (29)                                                                                                                         Wait-list (28)                                                    9 modules/9 weeks                                                   LSAS-SR                                                SIAS, SPS, SPSQ, BAI, MADRS-S, QOLI,                 19 (65.5%)              7 (24.1%)
  Sofie 3 ([@B77])              Students             SCID-I                              Social anxiety disorder                                                                       Guided CBT (19), guided CBT with group sessions (18)                                                                                    n.a.                                                              9 modules/9 weeks, 5 sessions                                       LSAS-SR                                                SIAS, SPS, SPSQ, BAI, MADR-S, QOLI                   22 (59.5%)              3 (8.1%)
  Sofie 4 ([@B78])              General population   SCID-I and II                       Social anxiety disorder                                                                       Guided CBT with discussion forum (40), unguided bibliotherapy (40)                                                                      Wait-list (40)                                                    9 modules/9 weeks                                                   LSAS-SR                                                SIAS, SPS, SPSQ, BAI, MADR-S, QOLI                   22 (55.0%)              10 (25.0%)
  Sofie 5 ([@B78])              General population   SCID I                              Social anxiety disorder                                                                       Guided AR (29), guided CBT with discussion forum (29), unguided bibliotherapy (29), unguided bibliotherapy with discussion forum (28)   n.a.                                                              9 modules/9 weeks                                                   LSAS-SR                                                SIAS, SPS, SPSQ, BAI, MADR-S, QOLI                   34 (63.0%)              27 (50.0%)
  Elsa ([@B79])                 General population   SCID-I                              Anxiety disorder with/without comorbid depression                                             Guided CBT (33)                                                                                                                         Wait-list with support (33)                                       8 modules/8 weeks [^l^](#fnT3_12){ref-type="table-fn"}              BAI                                                    MADRS-S, CORE-OM, PHQ-9, GAD-7, QOLI                 6 (27.3%)               3 (13.6%)
  Fobal spider ([@B80])         General population   SCID-I                              Specific phobia                                                                               Guided CBT (13), face-to-face CBT (14)                                                                                                  n.a.                                                              5 modules/4 weeks, 2 sessions [^h^](#fnT3_8){ref-type="table-fn"}   SPQ                                                    ADIS, FSS, BAI, BDI                                  12 (92.3%)              9 (69.2%)
  Gambling ([@B81])             General population   n.a.                                Gambling disorder                                                                             Guided CBT with discussion forum (317)                                                                                                  n.a.                                                              8 modules/8 weeks                                                   NODS                                                   HADS, QOLI                                           221 (93.6%)             194 (82.2%)
  Total                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1,027 (69.9%)           540 (35.2%)

SCID-I, structural clinical interview for DSM-IV axis I disorders; NOS, not otherwise specified; FAQ, frequently asked questions; BAI, beck anxiety inventory; BDI, beck depression inventory; QOLI, quality of life inventory; ISI, insomnia severity index; n.a., not applicable; ACT, acceptance and commitment herapy; LSAS-SR, Liebowitz social anxiety scale---self-report; PDSS-SR, panic disorder severity scale---self-report; PHQ-9, patient health questionnaire---nine items; GAD-7, generalized anxiety disorder---seven items; BA, behavioral activation; MADRS-S, montgomery--åsberg depression rating scale---self-report; IIEF-5, International Index of erectile functioning---five items; CBT, cognitive behavior therapy; IIEF, International index of erectile functioning; RAS, Relationship assessment scale; MINI, the MINI-International neuropsychiatric interview; BBQ, Brunnsviken brief quality of life inventory; Mini-SPIN, mini-social phobia inventory; HAM-D, Hamilton rating scale for depression; WAI, Working alliance inventory; CAPS, Clinician-administered PTSD scale for DSM-IV; IES-R, Impact of event scale---revised; PDS, Posttraumatic diagnostic scale; PSWQ, Penn ptate worry questionnaire; GAD-Q-IV, Generalized anxiety disorder questionnaire; CORE-OM, Clinical outcome in routine evaluation---outcome measure; STAI, State-trait anxiety inventory; CIDI, Composite international diagnostic interview; ACQ, Agoraphobic cognitions questionnaire; BSQ, Body sensations questionnaire; MI, Mobility inventory; DAS, Dyadic adjustment scale; MSI, Marital status inventory; SNAQ, Snake anxiety questionnaire; ADIS, anxiety disorders interview schedule; FSS, Fear Survey schedule; CBM, Cognitive bias modification; SIAS, Social interaction anxiety scale; SPS, Social phobia scale; SPSQ, Social Phobia screening questionnaire; AR, applied relaxation; SPQ, Spider phobia questionnaire; NODS, the NORC diagnostic screen for gambling problems.

\*Based on complete case analysis, i.e., only complete data.

Separate analyses of deterioration were conducted for the two primary outcome measures depending on the diagnosis of the patient.

Four treatment conditions were included in the study, with/without treatment rationale, respectively, but are pooled in the current analysis.

An additional outcome measure, International Physical Activity Questionnaire, IPAQ, was used in the study but is not included in the current analysis.

Passive control with the possibility to contact the research team if needed.

Patients were able to choose 10 out of 16 modules to be completed during 10 weeks.

Patients were able to choose 10 out of 19 modules to be completed during 10 weeks.

An additional treatment group, guided psychodynamic therapy, was also used in the study but is not included in the current analysis.

One brief orientation session and one session of 3-h prolonged exposure.

In addition to 2 weeks of CBM.

An additional treatment group, interpersonal psychotherapy, was also used in the study but is not included in the current analysis.

Additional outcome measures were included in the original study but lost in the raw data file.

Patients were able to complete up to eight modules selected by the therapist.

^1^Andersson G, Burman M, Norlander A-K, Magnusson K, Stalby M, Svensk M, et al. Internet-delivered couples therapy: a randomized controlled trial. (2019). Unpublished manuscript.

Response and Remission Rates {#s3_2}
----------------------------

Using the RCI criteria for detecting response, 1,027 (69.9%; 95% CI: 67.61--72.19) of the 1,535 participants receiving treatment were categorized as treatment responders when using an RCI of *z* = 1.96. The lowest rates were found in the trials on erectile dysfunction (12.1%) and older adults with anxiety (27.3%), whereas the highest rates were found in the trials on gambling (93.6%) and spider phobia (92.3%). As seen in [**Table 3**](#T3){ref-type="table"}, the proportions varied, which was confirmed by the CMA program showing a significant heterogeneity (*I* *^2\ =^* 87.5%; Q = 223, *p* \< .001).

Remission was achieved in 540 participants (35.2%; 95% CI: 32.81--37.59) when adjusting for floor effects (the unadjusted proportion was 31.9%). There was a large variation with ranging from 0% (erectile dysfunction, depression, and bias modification for social anxiety disorder) to 82% (gambling) and 69% (spider phobia). As with the response rates, a significant heterogeneity was found (*I* *^2\ =^* 91.6%; Q = 334, *p* \< .001).

Predictors of Response {#s3_3}
----------------------

Binomial logistic regressions were calculated with the predefined variables entered as predictors of response. Results are presented in [**Table 4**](#T4){ref-type="table"} with OR and 95% CI for each predictor. The results that indicate a higher symptom severity on the primary outcome measure at baseline was predictive of better outcome. The odds for responding to treatment decreased when having an anxiety disorder as compared to depression/mood disorder and other diagnoses (i.e., erectile dysfunction, relationship problems, and gambling disorder), and the odds increased if the subject was female. The other variables were not predictive of response.

###### 

Significance levels, odds ratios, and 95% confidence intervals (CI) for predictors of response.

  Predictor (*reference*)                                               OR     Lower CI   Upper CI   *p*
  --------------------------------------------------------------------- ------ ---------- ---------- --------
  Symptom severity at baseline (*lower severity*)                       1.36   1.12       1.65       \<.01
  Civil status (*single*)                                               1.20   0.75       1.91       .45
  Previous psychological treatment (*no*)                               0.77   0.50       1.19       .23
  Previous or ongoing psychotropic medication (*no*)                    0.94   0.58       1.54       .82
  Sick leave (*no*)                                                     0.41   0.16       1.06       .07
  Educational level (*below university level*)                          0.72   0.47       1.11       .14
  Age (*lower age*)                                                     1.01   0.99       1.02       .28
  Diagnosis, anxiety disorders (*depression/mood disorder and other*)   0.51   0.33       0.79       \<.01
  Gender (*male*)                                                       2.22   1.43       3.44       \<.001

OR, odds ratio; CI, 95% confidence interval; p, p-value.

We also repeated the analyses with remission as outcome (see [**Table 5**](#T5){ref-type="table"}). In this analysis, symptom severity at pre-treatment was marginally associated with less remission (OR = 0.81). As with the analysis for response, the odds for remission were lower if the subject suffered from anxiety. Gender and the other variables did not reach statistical significance. Publication year was unrelated to response and remission.

###### 

Significance levels, odds ratios, and 95% confidence intervals (CI) for predictors of recovery.

  Predictor (*reference*)                                               OR     Lower CI   Upper CI   *p*
  --------------------------------------------------------------------- ------ ---------- ---------- ---------
  Symptom severity at baseline (*lower severity*)                       0.81   0.66       1.00       .05
  Civil status (*single*)                                               0.98   0.59       1.64       .94
  Previous psychological treatment (*no*)                               0.65   0.41       1.04       .07
  Previous or ongoing psychotropic medication (*no*)                    1.33   0.77       2.30       .30
  Sick leave (*no*)                                                     0.65   0.21       2.00       .44
  Educational level (*below university level*)                          0.73   0.46       1.16       .18
  Age (*lower age*)                                                     1.00   0.99       1.02       .98
  Diagnosis, anxiety disorders (*depression/mood disorder and other*)   0.28   0.16       0.47       \< .001
  Gender (*male*)                                                       1.38   0.83       2.28       .21

OR, odds ratio; CI, 95% confidence interval; p, p-value.

Discussion {#s4}
==========

The aim of this IPDMA was to obtain estimates of response and remission rates for ICBT with a range of conditions categorized into three groups (anxiety, depression, and other). In line with a previous IPDMA on depression by Karyotaki et al. ([@B30]) which included trials from different countries, we found that 65.6% of the treated research participants could be classified as treatment responders. This is slightly higher than the 56.19% reported by Karyotaki et al. ([@B30]). While Karyotaki et al. ([@B30]) imputed missing data, they also reported that the estimates between complete case analysis and the imputed dataset were minor. In addition, we found that 35.0% of participants could be classified as having remitted, which is slightly lower than the 38.51% remission rate reported by Karyotaki et al. ([@B30]). Moreover, we had a problem with floor effects and if not considering that our estimate is even lower (31.9%). Overall, the results are rather similar to Karyotaki et al. ([@B30]) in that roughly half of clients showed improvement following ICBT and remission was achieved by a third.

Given these estimates, the outstanding question is how well this compares against face-to-face CBT. As previously mentioned, there are a few studies in which clients have been randomly assigned either face-to-face CBT or therapist-guided CBT. In the most recent of such study, Carlbring et al. ([@B5]) found no differences in effect. The response rates in CBT across different disorders and conditions are difficult to estimate; as to our knowledge, there is no similar IPDMA on response rates in face-to-face CBT. The closest we can get is a meta-analysis on anxiety disorders based on published data ([@B28]). In that review, 31% of the studies had defined response using RCI, and the results were similar to the range found in this analysis (44.5--51.1%). However, Loerinc et al. ([@B28]) also reported that the use of RCI in combination with a clinical cut-off (as was done in the present study) was associated with a 28% lower response rate (or, as expressed in this study, the remission rate was 28% lower than the RCI response rate). The difference we found was somewhat larger, as about half of the responders also showed remission. From a more naturalistic perspective, Gyani et al. ([@B82]) reported that 63.7% of participants in their clinical sample showed reliable improvement following evidence-based face-to-face treatment. In a recent meta-analysis, Springer et al. ([@B83]) reported a remission estimate as high as 51% (compared to our estimate of 35%). As stated by Loerinc et al. ([@B28]), there is a large variation in how to define both response and remission in CBT trials; thus, one advantage of the approach taken here is that we can use the same approach across studies. However, the definition of remission used (two SDs below the pre-treatment mean) was impossible in some studies (leading us to correct that estimate) and unrealistic in others. Another disadvantage of a statistical definition of response and remission is that it is heavily dependent on the sample upon which it is calculated. This pertains to both RCI and recovery as outlined by Jacobson and Truax ([@B29]). Another approach would have been to determine criteria for response and remission independently of the study, which is possible when there is data on non-clinical samples. For example, on the Beck Depression Inventory ([@B44]), a 10-point reduction could be seen as indicative of response, and 13-point reduction indicative of recovery. Applying these criteria for the Stella trial (see [**Table 3**](#T3){ref-type="table"}; [@B63]), in which 57.5% of participants responded according to the RCI and 0% remitted, the corresponding figures of using a 10-point reduction (53.1%) and a score of 13 or below on the BDI (59.4%) paints a slightly different picture (although the results are similar between the RCI criteria and the 10-point reduction). In particular, the difference between the 0% classified as remitters *versus* the 59.4% having a score indicating minimal depression ([@B44]) shows the importance of response definitions (for a detailed discussion, see [@B37]). However, in the present IPDMA, we found it to be of value to use similar criteria across trials. Future research could focus more on the external criteria of improvement instead of study-specific criteria. Unfortunately, the BDI is an exception, being widely used in many trials, and for some conditions and measures included in this IPDMA, cut-off scores and non-clinical norms have not been established.

In the present IPDMA, we conducted exploratory analyses to see if response could be predicted. It is important to note that there was no firm theoretical basis for our selection of predictors and, therefore, our findings must be interpreted with caution, as the identification of a significant predictor could have practical implications for future treatment recommendations. This is particularly the case when findings are based on samples larger than is commonly used in psychotherapy trials. However, the finding that symptom severity was not a negative predictor, but rather the opposite is in line with a previous IPDMA on low-intensity interventions for depression ([@B33]). From a clinical point of view, this makes sense, as having symptoms makes treatment more relevant than if subclinical or even different symptoms are present in the client. However, it also suggests that our ICBT trials probably included participants without severe symptoms. It is therefore possible that this finding is based on selection criteria used in trials and not necessarily relevant for clinical practice when treatment is offered with fewer restrictions. In contrast to the finding for response, we found a small negative effect of pre-treatment severity for the prediction of remission. These two conflicting results may indicate that large improvements are less likely if the client has more symptoms. However, as remission requires a low level of symptoms, it is less likely that a client with many symptoms will reach that low level. As in treatment research in general, it could be that the search for predictors is best pursued in ordinary clinical settings rather than in well-controlled trials. On a promising note, large ICBT effectiveness studies are being reported ([@B84]), which may provide clearer insight into the efficacy of different approaches for different populations.

The odds ratio in favor of female participants was surprisingly high (OR = 2.22), which is hard to explain as this is not a consistent result from previous individual trials. One possible explanation is the fact that the gender proportions in trials are nested with the condition treated. For example, in a typical depression trial, there is a majority of women, whereas in other conditions, there are more or less equal proportions of men and women, while some studies have only men (e.g., erectile dysfunction). The overall takeaway message here is that this finding needs further investigation in future trials to confirm its veracity. Gender was not found to be predictive of remission.

Interestingly, while the IPDMA by Karyotaki et al. ([@B30]) found old age to be weakly associated with better response (OR = 1.01), there was no such effect in this study suggesting that age is not a predictor of outcome. In Karyotaki et al.'s ([@B30]) complete case analyses, baseline severity (OR = 1.16) was found to predict better outcome, which was in line with our findings (but not in their intention to treat analyses). Gender did not predict outcome in Karyotaki et al.'s ([@B30]) IPDMA, but, again, their review focused on only depression which means a larger portion of the population was likely female.

In this IPDMA, we found decreased odds for responding to treatment when having an anxiety disorder as compared to depression/mood disorders or other (erectile dysfunction, relationship problems, and gambling disorder). This was a small effect, but still puzzling and hard to understand given that the overall picture is the opposite---indicating a higher response to ICBT in clients with anxiety disorders. Anxiety disorders were also found to be predictive of lower rates of remission.

While non-significant findings cannot be viewed as proof of absence of an effect, it is still interesting that ICBT has had marginal success in finding predictors of change as well as moderators and mediators of outcome ([@B1]). There are several possible reasons for this. First, participants in trials are not selected for their differences. Rather, they are chosen based on diagnostic criteria, access to the Internet, willingness to be a research participant, etc., all of which likely reduce the chance of identifying accurate predictors. Second, predictors of dropout ([@B85]) may ultimately be more illuminating, even if a given IPDMA was on self-guided ICBT for depressive symptoms. It is, however, interesting to note that they found that male gender (RR = 1.08) and co-morbid anxiety symptoms (RR = 1.18) significantly increased the risk of dropping out of the study, which is in line with our findings with regards to gender and anxiety disorders. In spite of the overall inconsistency in findings and lack of findings, we believe that IPDMA is a powerful and reliable tool for answering questions regarding predictors of response ([@B86]). However, this will require concerted efforts to align both outcome measures as well as data on predictors in order to make studies comparable. Even if we were co-workers and principal investigators in the trials included in this IPDMA, the data were not consistent with regards to background variables etc. It becomes even more problematic when attempting to combine datasets from different research groups.

This study had several limitations. We focus on four, knowing that there are further objections that could be raised. First, we only included our own trials, which were conducted in Sweden. IPDMAs are often selective, as original data sometimes cannot be obtained from authors, but in this case, we cannot generalize the results outside of our own culture and setting. In addition to not including trials from international groups, we also did not include the most recent and unpublished trials from our own groups, and there are other groups in Sweden with trials that were also not included. Furthermore, with the focus on our own studies conducted over a period close to 20 years, there is a possibility of time trends, which we did not focus on in this study. Technological changes may not influence effects, but, to give an example, early studies relied more on printing out text materials ([@B87]), whereas recent studies are typically delivered *via* online platforms (e.g., responsive to the presentation format, such as smartphones or computers) ([@B2]). Second, even if this limitation is not unique for ICBT, outcome measures were largely based on self-report. Such measures are useful and generally have good psychometric properties but still present a possible risk that self-reported changes do not correspond with actual behavior changes and do not conform to the findings of an interview. Third, as commented on by Loerinc et al. ([@B28]), treatment response can be defined by several measures, but here, we focused only on the primary outcomes. Our dataset on IPDMA could also be used to analyze effects on other secondary measures of constructs, like quality of life, as several of our studies have used the same measure for this construct (e.g., [@B88]), and it has been reported that the effects of ICBT might be lower on that construct ([@B89]). The fourth limitation relates to the statistical methods used. We decided to report on a complete case basis, but we could not exclude bias, as missing data was not considered.

Conclusions {#s5}
===========

In spite of the limitations, the present IPDMA suggests that ICBT can lead to major reductions in symptoms and that more than half of clients, on average, respond to treatment. A lower proportion remits; thus, there is room for improvement. It is possible that women benefit more from ICBT based on our findings, and symptom severity seems to be predictive of outcome, but these findings should be interpreted with caution. Our findings that studies on clients with anxiety disorders were associated with less response is also notable but should be regarded with care. Future IPDMAs should include more trials and should also consider secondary outcomes, such as quality of life.
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